Patients with R172-m had significantly slower blast clearance than patients with R140-m, despite no difference in outcomes. (A) Time to blast clearance. Kaplan-Meier curves for estimated time to blast clearance (defined as days from induction to first BMB with ≤5% blasts, censored at time of second treatment or death) demonstrate significantly slower blast clearance among patients with R172-m. Median days to blast clearance was 44 among patients with R172-m vs 24 days among patients with R140-m (P = .017). There was no significant effect of induction type or of addition of enasidenib to induction. (B) Overall survival. Kaplan-Meier curves for estimated overall survival reveal no difference between patients with R140-m vs patients with R172-m. Estimated 24-month survival was 78% (67%, 91%); 74% (60%, 91%) among patients with R140-m and 89% (76%, 100%) among those with R172-m.